key: cord-0252366-zcwj0x6b authors: Caio, Giacomo; Lungaro, Lisa; Cultrera, Rosario; Giorgio, Roberto De; Volta, Umberto title: Coronaviruses and gastrointestinal symptoms: an old liaison for the new SARS-CoV-2 date: 2020 journal: Gastroenterol Hepatol Bed Bench DOI: nan sha: 8cb181cb74f58fd033ce3affd42b5327b4011876 doc_id: 252366 cord_uid: zcwj0x6b The coronavirus disease (Covid-19) has caused a pandemic with more than 600,000 deaths to date. It is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a member of the beta-coronavirus genus that also includes SARS and the Middle East Respiratory Syndrome Coronavirus (MERS). While the typical presentation is given by respiratory symptoms and fever, some patients also report gastrointestinal symptoms such as diarrhea, nausea, vomiting, and abdominal pain. Several studies have identified the SARS-CoV-2 RNA in stool specimens of infected patients, and its viral receptor angiotensin-converting enzyme 2 (ACE2) is highly expressed in enterocytes. In this short review, we report the frequency of gastrointestinal symptoms in infected patients and suggest possible implications for disease management, transmission, and infection control. The novel coronavirus disease (COVID-19) has been spreading rapidly across the world, affecting more than 178 countries and causing more than 1.000.000deaths to date. COVID-19 is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a member of the Beta-coronavirus genus that also includes SARS-CoV and the Middle East Respiratory Syndrome Coronavirus (MERS-CoV). COVID-19 patients typically present with various respiratory manifestations ranging from mild flu-like symptoms (e.g., rhinitis, cough, sore throat, fever, joint/muscle pain) to severe life-threatening interstitial pneumonia (1) . In addition, some patients report gastrointestinal (GI) symptoms such as diarrhea, nausea, vomiting, and abdominal pain in combination with the above-cited Orthocoronavirinae or Coronaviruses (CoVs) are a sub-family of the Coronaviridae family, a group of single-stranded enveloped RNA viruses. They were identified during the 1960s and are known to infect animals and human epithelial cells in both the respiratory system and the GI tract (4) (5) (6) . It is well known that CoVs sub-family viral shedding occurs via airways and the digestive system. For this reason, the transmission may occur not only through airborne droplets and fomites but also through the oro-fecal route (7) . The CoVs sub-family is further subdivided into four genera, alpha, beta, gamma, and delta, based on their genetics and capacity to infect primarily (but not exclusively) mammals (alpha and beta) and birds (gamma and delta) (8) . Until the end of 2019, only six species of CoVs wherewere known to infect humans, i.e. i) Coronavirus (CoV)-229E; ii) CoV-NL229E (from alpha-CoV genus); iii) CoV-OC43; iv) CoV-HKU1; v) Severe Acute Respiratory Syndrome (SARS)-CoV, and vi) Middle East Respiratory Syndrome (MERS)-CoV (all from beta-CoV genus). Notably, CoV-229E, -NL229E, -OC43, and -HKU1, also labelled as "Human CoVs unrelated to Severe Acute Respiratory Syndrome" (non-SARS HCoVs), are commonly isolated from children with acute gastroenteritis. Their significance as pediatric GI pathogens appears minor, however, as most of the HCoV findings in stools were co-infections with known gastroenteritis viruses (e.g., rotavirus and norovirus), but no definitive conclusions have been drawn (9) . In 2003, SARS-CoV spread to over 30 countries, causing a respiratory disease with a mortality rate of about 8% (10) . Phylogenetic analyses showed that the SARS-CoV genome is a result of a recombination of six different CoVs, namely: the porcine epidemic diarrhea virus (PEDV), transmissible gastroenteritis virus (TGEV), bovine coronavirus (BCoV), human CoV-229E, murine hepatitis virus (MHV), and the avian infectious bronchitis virus (IBV) (11) . From a genetic standpoint, it is quite clear that SARS-CoV has a tropism for enterocytes, and as a result, GI symptoms were commonly reported in the SARS outbreak. About 20% of SARS patients had diarrhea on disease presentation (10, 12) , and up to 73% presented with diarrhea mainly during the first week of disease with a 16 53 35 (66.0%) 6 (11.3%) 5 (9.4%) Leung CW et al. 17 44 9 (20.5%) 13 (29.5%) 4 (9.1%) Jang TN et al. 18 62 62 3 (4.8%) N/A N/A Huang C et al. 63 38 64 137 65 52 66 45 67 77 1 (1.3%) 6 (7.8%) N/A Xu H et al. 68 1324 28 (2.1%) N/A N/A Huang R et al. 69 202 13 (6.43%) N/A N/A Qi D et al. 70 267 10 (3.7%) 6 (2.2%) N/A Yang P et al. 71 77 168 12 (7.1%) 9 (5.3%) 7 (4.2%) Ma L et al. 78 81 6 (7.4%) N/A N/A Yao N et al. 79 40 3 (7.5%) 3 (7.5%) N/A Liu S et al. 80 620 53 (8.5%) N/A N/A Chen X et al. 81 291 83 153 14 (9.1%) 3 (2%) 1 (0.6%) Fu H et al. 84 36 85 75 7 (9.3%) N/A 1 (1.3%) Liu Y et al. 86 109 12 (11%) N/A N/A Fan L et al. 87 55 6 (10.9%) 4 (7.3%) N/A Zhang JJ et al. 88 139 89 52 7 (13.4%) 1 (1.9%) N/A Han R et al. 90 108 15 (13.9%) N/A N/A Ai J et al. 91 102 15 (14.7%) 9 (8.8%) 3 (2.9%) Wang L et al. 92 18 3 (16.7%) N/A N/A Lin L et al. 93 95 23 (24.2%) 17 (17.9%) 2 (2.1%) Chen Q et al. 94 9 2 (22.2%) 0 (0%) 0 (0%) Xu S et al. 95 355 130 (36.6%) N/A N/A Korea Centers for Disease Control and Prevention 96 28 2 (7.1%) 0 (0%) 1 (3.6%) Tabata S et al. 97 104 10 (9.6%) N/A N/A Cholankeril G et al. 98 (13, 14) . Analyzing the published papers reporting GI symptoms in SARS (Table 1) , diarrhea was present in 376 out of 1270 studied patients (29.6% of cases, ranging from 13.8% to 73%), nausea in 79/408 (19.4%, ranging from 11.3% to 29.5%), vomiting 78/675 (11.5%, ranging from 9.4% to 29.5%), and abdominal pain in 14/241 (5.8%, ranging from 5.0% to 9.4% (Table 1 ) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) . SARS-CoV was subsequently found in the feces of patients, and in some cases, the RNA presence persisted even after thirty days from disease onset (25) . The SARS-CoV pathophysiological mechanism leading to cell infection and following viral replication occurs by binding of the envelope-anchored spike viral protein to a host receptor leading to a fusion of the SARS-CoV with targeted cell membranes. Evidence indicates that a defined receptor-binding domain (RBD) of SARS-CoV spike protein specifically recognizes the ACE2 expressed in type 2 alveolar cells as well as in the gut and several other tissues and organs (e.g., kidneys, endocrine tissues, liver, etc.) (26, 27) . In 2012, MERS-CoV was identified as a zoonotic virus causing human respiratory disease (28) with 2494 cases (mainly in Saudi Arabia and Korea) and 858 deaths (34.4% mortality rate) (29) . GI symptoms were the most commonly reported extrapulmonary clinical features of MERS, and about one-third of patients suffered from abdominal pain, nausea, vomiting, and diarrhea (30, 31) . GI symptoms were present at disease onset in about 25% of patients, some of whom experienced fever and GI complaints before respiratory symptoms (30, 32) . MERS-CoV RNA was found in patients' feces in about 15% of cases (33) . The mechanism used by MERS-CoV to infect and replicate in human cells occurs via the dipeptidyl peptidase 4 receptor (DPP4), a protein mainly expressed by endothelium and enterocytes, and even in the blood in a soluble form (34) . Experimental studies have demonstrated that MERS-CoV could replicate primarily in enterocytes via DPP4 and then spread to the lungs, which suggests that in some cases, pneumonia is secondary to intestinal infection (35) . Human intestinal epithelial cells are highly susceptible to MERS-CoV, providing a strong viral replication environment. This would explain some cases of MERS caused by the consumption of unpasteurized camel milk or undercooked camel meat via the oro-fecal route (36) . Indeed, MERS-CoV RNA could be detected in 41.7% of milk samples collected from lactating camels, which shed the virus in nasal secretion and/or feces (35, 37) . The prevalence of GI symptoms in MERS patients is summarized in Table 2 (30, (38) (39) (40) (41) (42) (43) (44) (45) (46) . At the end of 2019, a new coronavirus was identified as the etiological agent of a cluster of interstitial pneumonia cases in the Chinese city of Wuhan (47) . The World Health Organization and Coronaviridae Study Group of the International Committee on Taxonomy of Viruses termed the novel coronavirus SARS-CoV-2, and the related disease was referred to as "COronaVIrus Disease 2019" (hence, 'COVID-19') (47, 48) . The genome sequence of SARS-CoV-2 is 98% similar to SARS-CoV-1 and 50% similar to MERS (49) . Both SARS-CoV and SARS-CoV-2 encode and express the spike protein that binds to the ACE2 receptor to enter human cells (27, 50) . The RBD domain confers higher affinity to SARS-CoV-2 than SARS-CoV to bind the human ACE2, a feature which correlates with the efficient spread of the virus among humans and the ability to infect tissues even with low ACE2 expression (51, 52) . Based on these pathophysiological mechanisms and the previously quoted molecular and clinical studies performed on SARS-CoV-1 and SARS-CoV-2, it is quite clear that the new virus can infect enteric cells and be spread via the oro-fecal route (10, 12-14, 25-27, 49-52) . The tropism for the GI tract has been confirmed by staining visualization of the viral nucleocapsid proteins of SARS-CoV-2 in the cytoplasm of gastric, duodenal, and rectal epithelial cells (53) . Although at a lower frequency than SARS and MERS, some COVID-19 patients show GI symptoms such as diarrhea, nausea/vomiting, and abdominal pain during the course of the disease, although rarely as a unique manifestation (2) ( Table 3 ) . Explanations for the different frequencies of GI clinical manifestations can be found in the complex pathogenesis, in the host-virus interaction mediated by the immune system, and the different microbiota composition in the gut and airways (111) . The ACE2 expression in the gut is not intrinsically a condition sufficient for the virus to enter into enterocytes. Several other proteins of the host are involved in the ACE2 signalling network, such as the transmembrane protease serine 2 (TMPRSS-2), cathepsin B (CTPB), cathepsin L (CTPL), DPP4, aminopeptidases (ANPEP), monocyte chemoattractant protein-1 (MCP-1/CCL2), transferrin receptor (TFRC), meprin A subunit alpha (MEP1A), disintegrin, metalloproteinase domain 17 (ADAM17), fatty-acid binding protein 2 (FABP2), intracellular cholesterol transporter (NPC1), and C-Type Lectin Domain Family 4 Member M (CLEC4M) (112) . Recently, it was demonstrated that the virus could enter human cells without using ACE2. An alternative receptor, CD147, has been described as a new route for SARS-CoV-2 infection, thus bypassing ACE2 and its pathway (113) . Taken this information together, it is quite clear that SARS-CoV-2 infection and damage to GI cells occur through a variety of molecular targets rather than being mediated solely via ACE2. Indeed, following the latter erroneous hypothesis, the gut would be the main target for COVID-19, as it expresses 70 times more ACE2 than the lungs (3), whereas intestinal symptoms are present in less than 15% of COVID-19 patients. The origin of GI symptoms in patients affected by COVID-19 remains to be clarified, as many patients with the live virus present in stools do not have intestinal complaints (114) . Despite the presence of live virus in the stools, the oro-fecal spreading mechanism has not been fully demonstrated. Most patients may have very little traces of non-vital virus RNA in feces detected by RT-PCR, and only a minority have a vital virus at a low viral load unable to infect a new host (2) . For this reason, there is still inadequate evidence to support stool testing for the diagnosis or monitoring of COVID-19 patients. Even the GI symptoms are of uncertain origin in patients with COVID-19, being caused by active viral replication in the gut in some patients or attributed to other causes, including pharmacologic treatments such as non-steroidal antiinflammatory drugs (NSAIDs), antibiotics (azithromycin), and antiviral agents. In this context, the likely occurrence of gut dysbiosis, i.e. changes in the richness and diversity of the normal composition of the gut microbiota, along with altered epithelial cell permeability may participate to GI symptom generation in patients with COVID-19. One may think that GI symptoms result from an impaired anatomomicrobiological functional barrier constituted by enterocytes, tight-junctions, mucus, microbiota, and the immune system triggered by SARS-CoV-2 infection acting in concert with other noxious factors, e.g., other pathogens and/or drugs (some of them commonly used in clinical practice, such as NSAIDs) (115) . The alteration of the intestinal barrier and dysbiosis along with gastrointestinal infections and psychosocial distress are the main pathophysiological mechanisms underlying functional GI disorders (FGIDs) such as post-infectious irritable bowel syndrome (PI-IBS) and functional dyspepsia (PI-FD) (116) . COVID-19 is a paradigm for the proposed pathogenetic mechanisms, involving post-infective gut dysbiosis along with psychosocial distress due to the lockdown and loss of relatives and work. Clearly, further studies are necessary to establish the impact of the COVID-19 pandemic on the new onset of IBS and FD. In conclusion, physicians should avoid overlooking or under evaluating GI symptoms in COVID-19 patients. The primary aim is to manage nausea, vomiting, and diarrhea via symptomatic treatment options along with the use of probiotics to limit or control the occurrence of intestinal dysbiosis. In daily practice, it is recommended to exclude other common causes of intestinal symptoms, such as Clostridium difficile infection, particularly in hospitalized patients. Finally, since GI symptoms alone are quite rare in COVID-19 patients (being detectable in less than 3% of cases), routine SARS-CoV-2 stool test is not indicated and, to the best of our knowledge, it should be performed only in patients with negative nasopharyngeal swabs in the presence of clear imaging features indicative of interstitial pneumonia. Clinical Characteristics of Coronavirus Disease 2019 in China Meta-Analysis of International Data, and Recommendations for the Consultative Management of Patients with COVID-19 Digestive system is a potential route of COVID-19: an analysis of single-cell coexpression pattern of key proteins in viral entry process The coronaviruses Age dependent resistance to transmissible gastroenteritis of swine (TGE) II. Coronavirus titer in tissues of pigs after exposure Pleomorphic virus-like particles in human faeces Coronavirus propagated from patient with non-bacterial gastroenteritis Lefkowitz EJ editors. Virus Taxonomy, the 9th Report of the International Committee on Taxonomy of Viruses. Family Coronaviridae Detection of human coronaviruses in children with acute gastroenteritis A major outbreak of severe acute respiratory syndrome in Hong Kong Testing the hypothesis of a recombinant origin of the SARS-associated coronavirus Enteric involvement of severe acute respiratory syndrome-associated coronavirus infection Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area Clinical and laboratory features of severe acute respiratory syndrome vis-a-vis onset of fever Severe acute respiratory syndrome among children Severe acute respiratory syndrome in Taiwan: analysis of epidemiological characteristics in 29 cases A major outbreak of severe acute respiratory syndrome in Hong Kong Outcomes and prognostic factors in 267 patients with severe acute respiratory syndrome in Hong Kong Viral replication in the nasopharynx is associated with diarrhea in patients with severe acute respiratory syndrome Enteric involvement of severe acute respiratory syndrome-associated coronavirus infection Severe acute respiratory syndrome-related diarrhea Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study Detection of SARS coronavirus in patients with suspected SARS Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus World Health Organization, MERS-CoV Outbreak Update (World Health Organization Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease MERS coronavirus: diagnostics, epidemiology and transmission Viral Shedding and Antibody Response in 37 Patients With Middle East Respiratory Syndrome Coronavirus Infection Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system Human intestinal tract serves as an alternative infection route for Middle East respiratory syndrome coronavirus Human infection with MERS coronavirus after exposure to infected camels, Saudi Arabia Middle East respiratory syndrome coronavirus (MERS-CoV) RNA and neutralising antibodies in milk collected according to local customs from dromedary camels Critically Ill Patients With the Middle East Respiratory Syndrome: A Multicenter Retrospective Cohort Study Clinical Presentation and Outcomes of Middle East Respiratory Syndrome in the Republic of Korea High fatality rates and associated factors in two hospital outbreaks of MERS in Daejeon, the Republic of Korea Epidemiologic features of the first MERS outbreak in Korea: focus on Pyeongtaek St. Mary's Hospital Middle East respiratory syndrome coronavirus in Al-Madinah City, Saudi Arabia: Demographic, clinical and survival data Clinical aspects and outcomes of 70 patients with Middle East respiratory syndrome coronavirus infection: a single-center experience in Saudi Arabia Presentation and outcome of Middle East respiratory syndrome in Saudi intensive care unit patients Treatment outcomes for patients with Middle Eastern Respiratory Syndrome Coronavirus (MERS CoV) infection at a coronavirus referral center in the Kingdom of Saudi Arabia Hospital outbreak of Middle East respiratory syndrome coronavirus The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2 Director-General's remarks at the media briefing on 2019-nCoV on 11 Genomic characterization of the 2019 novel humanpathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation A Comparative Study on the Clinical Features of Coronavirus 2019 (COVID-19) Pneumonia With Other Pneumonias Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan Clinical Characteristics of Coronavirus Disease 2019 in China Clinical course and risk factors for mortality of adult in patients with COVID-19 in Wuhan, China: a retrospective cohort study Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study Clinical Characteristics of COVID-19 Patients With Digestive Symptoms in Hubei, China: A Descriptive, Cross-Sectional, Multicenter Study Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study SARS-CoV-2 Infection in Children Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study Clinical findings in critical ill patients infected with SARS-Cov-2 in Guangdong Province, China: a multi-center, retrospective, observational study Clinical characteristics and durations of hospitalized patients with COVID-19 in Beijing: a retrospective cohort study Analysis and prediction of false negative results for SARS-CoV-2 detection with pharyngeal swab specimen in COVID-19 patients: a retrospective study Clinical findings of patients with coronavirus disease 2019 in Jiangsu province, China: A retrospective, multi-center study Epidemiological and clinical features of 2019-nCoV acute respiratory disease cases in Chongqing municipality, China: a retrospective, descriptive, multiple-center study Epidemiological and clinical features of COVID-19 patients with and without pneumonia in Beijing, China Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China Don't Overlook Digestive Symptoms in Patients With 2019 Novel Coronavirus Disease (COVID-19) Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2 A descriptive study of the impact of diseases control and prevention on the epidemics dynamics and clinical features of SARS-CoV-2 outbreak in Shanghai, lessons learned for metropolis epidemics prevention Epidemiological and clinical characteristics of COVID-19 in Shenzhen, the largest migrant city of China Clinical characteristics of coronavirus disease 2019 in Hainan Effect of SARS-CoV-2 infection upon male gonadal function: a single center-based study Clinical characteristics and influencing factors of patients with novel coronavirus pneumonia combined with liver injury in Shaanxi region Clinical characteristics and risk factors of patients with severe COVID-19 in Jiangsu province, China: a retrospective multicentre cohort study Epidemiological and clinical features of 291 cases with coronavirus disease 2019 in areas adjacent to Hubei Clinical Characteristics of Moderate COVID-19 Patients Aggravation in Wuhan Stadium Cabin Hospital: A 571 Cases of Retrospective Cohort Study A preliminary study on serological assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 238 admitted hospital patients Analysis on the clinical characteristics of 36 cases of novel coronavirus pneumonia in Kunming Clinical and laboratory profiles of 75 hospitalized patients with novel coronavirus disease Clinical features and progression of acute respiratory distress syndrome in coronavirus disease 2019 Medical treatment of 55 patients with COVID-19 from seven cities in northeast China who fully recovered: a single-center, retrospective, observational study Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan Association between clinical, laboratory and CT characteristics and RT-PCR results in the follow-up of COVID-19 patients Early Clinical and CT Manifestations of Coronavirus Disease 2019 (COVID-19) Pneumonia The cross-sectional study of hospitalized coronavirus disease 2019 patients in Xiangyang Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection A report of clinical diagnosis and treatment of nine cases of coronavirus disease 2019 COVID-19 National Emergency Response Center, Epidemiology and Case Management Team, Korea Centers for Disease Control and Prevention. Early Epidemiological and Clinical Characteristics of 28 Cases of Coronavirus Disease in South Korea Clinical characteristics of COVID-19 in 104 people with SARS-CoV-2 infection on the Diamond Princess cruise ship: a retrospective analysis High Prevalence of Concurrent Gastrointestinal Manifestations in Patients With Severe Acute Respiratory Syndrome Coronavirus 2: Early Experience From California COVID-19 National Incident Room Surveillance Team. COVID-19 The Characteristics of 50 Hospitalized COVID-19 Patients With and Without ARDS Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore SARS-CoV-2 infection in 86 healthcare workers in two Dutch hospitals in Gastrointestinal Symptoms and Coronavirus Disease 2019: A Case-Control Study From the United States Gastrointestinal and Hepatic Manifestations of 2019 Novel Coronavirus Disease in a Large Cohort of Infected Patients From New York: Clinical Implications Virological assessment of hospitalized patients with COVID-2019 Use of siltuximab in patients with COVID-19 pneumonia requiring ventilatory support Investigation of three clusters of COVID-19 in Singapore: implications for surveillance and response measures Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study Enteric involvement in hospitalised patients with COVID-19 outside Wuhan Evidence for Gastrointestinal Infection of SARS-CoV-2 The Gut-Lung Axis in Health and Respiratory Diseases: A Place for Inter-Organ and Inter-Kingdom Crosstalks ACE2 interaction networks in COVID-19: a physiological framework for prediction of outcome in patients with cardiovascular risk factors SARS-CoV-2 invades host cells via a novel route: CD147-spike protein Detection of SARS-CoV-2 in Different Types of Clinical Specimens Diarrhea During COVID-19 Infection: Pathogenesis, Epidemiology, Prevention, and Management Rome Foundation Working Team Report on Post-Infection Irritable Bowel Syndrome The authors declare that they have no conflict of interest.